Renoprotective effects of a novel inhibitor of advanced glycation

Diabetologia

Volumn 44, Issue 1, 2001, Pages 108-114

  Forbes, J M ^a   Soulis, T ^a   Thallas, V ^a   Panagiotopoulos, S ^a   Long, D M ^a   Vasan, S ^b   Wagle, D ^b   Jerums, G ^a   Cooper, M E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Alteon Inc   (United States)

Author keywords

Albuminuria; Aminoguanidine; Glycation; Nephropathy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; ALT 946; AMIDE; AMINOGUANIDINE; GLUCOSE; HEMOGLOBIN A1C; N (2 ACETAMIDOETHYL)HYDROZINE CARBOXIMIDAMIDE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG POTENCY; GLUCOSE BLOOD LEVEL; GLYCATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN URINE LEVEL; RAT; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ANIMALS; CROSS-LINKING REAGENTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; ENZYME INHIBITORS; GLOMERULAR FILTRATION RATE; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY GLOMERULUS; MALE; NITRIC OXIDE SYNTHASE; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN, BOVINE;

EID: 0035125966     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051587     Document Type: Article

References (24)

1. Advanced protein glycosylation in diabetes and aging
2. Protein glycation in the kidney: Role in diabetes and aging
3. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat
4. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction
5. Role of EDRF (Nitric oxide) in diabetic renal hyperfiltration
6. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes
7. The effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment
8. Identification of new inhibitors of AGE-protein crosslinking using a novel ELISA
9. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
10. Enzymatic determination of glucose and fructose simultaneously
11. Glomerular filtration rate in streptozocin-induced diabetic rats. Role of exchangeable sodium, vasoactive hormones, and insulin therapy
12. Validation in awake rats of a tail-cuff method for measuring systolic pressure
13. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats
14. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM
15. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation
16. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195
17. A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes
18. Chronic dosing with aminoguanidine and novel advanced glycosylation end product formation inhibitors ameliorates cross-linking of tail tendon collagen in streptozotocin-induced diabetic rats
19. Are the renoprotective effects of aminoguanidine in diabetes mediated via its action as a NO synthase inhibitor?
20. Current concepts of renal hemodynamics in diabetes
21. Early glycosylation products induce glomerular hyperfiltration in normal rats
22. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy
23. Vascular hypertrophy in experimental diabetes: Role of advanced glycation end products
24. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat